An observational study in Respiratory Tract Infections (RTI), Influenza -Like Illness and Influenza, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Influenza, Human with a site in France — 11 open to participants now, 12 under way, 3 of them phase 3. Influenza, Human · France.
Among the 103 studies in Influenza, Human with a site in France, this one is the 2nd largest by planned enrollment of the 24 observational ones that give a count, is one of 3 that started in 2026, is one of 24 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 101st registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →11 of the 103 studies in Influenza, Human with a site in France are open now. Recruiting first, the newest first:
University Hospital, Caen · Sites in France
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–100
Hospices Civils de Lyon · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Bordeaux · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 21 · Phase 3 27 · Phase 4 8
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25,000 is above the median of 403 across 335 observational studies indexed under Influenza, Human.
Median enrollment 312 across the 79 interventional studies, 431 across the 24 observational. Of the 81 that completed or were terminated, 25 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 103 have an industry lead sponsor. The 10 most frequent:
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Institut National de la Santé Et de la Recherche Médicale, France has 8 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
5 of the studies in Influenza, Human with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06254313University Hospital, BordeauxThe Role of Cxcr4Hi neutrOPhils in InflueNza | 2026-12 |
| NCT07882186Assistance Publique - Hôpitaux de ParisAssessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region | 2027-03 |
| NCT06907667Centre Hospitalier Universitaire de NiceStudy of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure | 2027-03 |
| NCT06643039Hospices Civils de LyonNosocomial Respiratory Virus Infection | 2027-07-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 103 studies in Influenza, Human with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs). These viruses can cause epidemics of varying severity, requiring close monitoring to determine their circulation levels and adapt public health measures accordingly. In France, ARI surveillance relies on two networks: the Sentinelles network in primary care and the RENAL network in hospitals. The Sentinelles surveillance is conducted in collaboration with Santé publique France, the National Reference Center for Respiratory Infection Viruses (Institut Pasteur and Hospices Civils de Lyon), and the University of Corsica. As part of the virological surveillance of ARIs, Sentinelles physicians are asked to collect nasopharyngeal swabs or saliva samples from a sample of patients presenting with an ARI during their clinic visits. This surveillance makes it possible to identify respiratory viruses circulating in primary care (general practice and pediatrics), to describe confirmed cases for each of the circulating viruses, and to estimate the impact of each on general practice. This surveillance also allows for the evaluation of the effectiveness of vaccines against influenza and COVID-19.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
This study's planned enrollment of 25,000 is above the median of 403 across 335 observational studies indexed under Influenza, Human.
Browse Influenza, Human studies →Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Compared within Influenza, Human, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Tract Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients seen in GPs' consultation with an acute respiratory infection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: saliva sampling · Diagnostic Test: Nasopharyngeal swab
Based on the protocol, physicians perform either a nasopharyngeal swab or saliva collection on included patients. The method is determined by scientific data and epidemiological constraints, not by the patient. Saliva collection: The physician oversees the collection during the visit using the provided kit (pipette, tube, etc.). Depending on constraints, the patient may perform the collection at home if agreed upon. If the patient is unable to self-collect (e.g., infants, facial paralysis), the physician collects the saliva directly from under the tongue using the pipette.
Based on the protocol, physicians perform either a nasopharyngeal swab or saliva collection on included patients. The method is determined by scientific data and epidemiological constraints, not by the patient. Nasopharyngeal sampling: During the consultation, the physician performs a deep nasal swab using the provided kit (FFP2 mask, swab, transport tube, absorbent, SafetyBag, and pre-paid envelope for partner labs).
Proportion of acute respiratory infection (ARI) cases seen in private practice (general practice and pediatrics) that tested positive for influenza viruses (by type and subtype), SARS-CoV-2, RSV, rhinovirus, and metapneumovirus
Time frame: Baseline
Weekly incidence rate of acute respiratory infections caused by influenza viruses and SARS-CoV-2 seen in general practice
Time frame: Baseline
Proportion of patients included vaccinated against influenza
Time frame: Baseline
Started May 2026 (actual). Primary completion is estimated for May 2031, 60 months after the start.
Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 60 months is above that.
Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →